Emergence of Treatment for multiple sclerosis patients failed in treatment
Multiple sclerosis(MS) patients who failed in treatment have now found an alternative.
The Ministry of Health and Welfare decided to accept the health insurance benefit of Genzyme’s ‘Lemtrada(alemtuzumab)’ on relapsing-remitting multiple sclerosis(RRMS) patients who failed in treating the diseas...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
